Table of Contents
Last Updated: August 8, 2022
Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
- Overview of COVID-19
- Testing for SARS-CoV-2 Infection
- Prevention of SARS-CoV-2 Infection
- Clinical Spectrum of SARS-CoV-2 Infection
- Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints
- Clinical Management of Adults Summary
- General Management of Nonhospitalized Patients With Acute COVID-19
- Therapeutic Management of Nonhospitalized Adults With COVID-19
- Therapeutic Management of Hospitalized Adults With COVID-19
Clinical Management of Children
- Clinical Management of Children Summary
- Special Considerations in Children
- Therapeutic Management of Nonhospitalized Children With COVID-19
- Therapeutic Management of Hospitalized Children With COVID-19
- Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])
- Care of Critically Ill Adults With COVID-19 (Summary Recommendations)
- Introduction to Critical Care Management of Adults With COVID-19
- Hemodynamics for Adults
- Oxygenation and Ventilation for Adults
- Pharmacologic Interventions for Critically Ill Patients
- Extracorporeal Membrane Oxygenation for Adults
- Introduction to Critical Care Management of Children With COVID-19
- Hemodynamic Considerations for Children
- Oxygenation and Ventilation for Children
- Extracorporeal Membrane Oxygenation for Children
- Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
- Remdesivir
- Table 4a. Remdesivir: Selected Clinical Data
- Ritonavir-Boosted Nirmatrelvir (Paxlovid)
- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
- Molnupiravir
- Interferons
- Table 4b. Interferons: Selected Clinical Data
- Ivermectin
- Table 4c. Ivermectin: Selected Clinical Data
- Table 4d. Characteristics of Antiviral Agents
Anti-SARS-CoV-2 Antibody Products
- Anti-SARS-CoV-2 Antibody Products (Summary Recommendations)
- Anti-SARS-CoV-2 Monoclonal Antibodies
- Table 5a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
- COVID-19 Convalescent Plasma
- Table 5b. COVID-19 Convalescent Plasma: Selected Clinical Data
- Immunoglobulins: SARS-CoV-2 Specific
- Table 5c. Characteristics of SARS-CoV-2 Antibody-Based Products
Cell-Based Therapy Under Evaluation for the Treatment of COVID-19
- Immunomodulators Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
- Corticosteroids
- Table 6a. Systemic Corticosteroids: Selected Clinical Data
- Table 6b. Inhaled Corticosteroids: Selected Clinical Data
- Interleukin-6 Inhibitors
- Table 6c. Interleukin-6 Inhibitors: Selected Clinical Data
- Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
- Table 6d. Kinase Inhibitors: Selected Clinical Data
- Colchicine
- Fluvoxamine
- Table 6e. Fluvoxamine: Selected Clinical Data
- Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
- Table 6f. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
- Immunoglobulins: Non-SARS-CoV-2 Specific
- Interleukin-1 Inhibitors
- Table 6g. Characteristics of Immunomodulators
Antithrombotic Therapy in Patients With COVID-19
- Table 7a. Antithrombotic Therapy: Selected Clinical Data
- Table 7b. Antiplatelet Therapy: Selected Clinical Data
- Supplements (Summary Recommendations)
- Vitamin C
- Vitamin D
- Zinc
Considerations for Using Concomitant Medications in Patients With COVID-19
- Special Considerations in People Who Are Immunocompromised
- Special Considerations in Adults and Children With Cancer
- Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
- Special Considerations in People With HIV
- Influenza and COVID-19
- Special Considerations in Pregnancy
Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members